Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction

被引:66
作者
Rajagopalan, P
Mazzu, A
Xia, CH
Dawkins, R
Sundaresan, P
机构
[1] Bayer Corp, Dept Clin Pharmacol, Div Pharmaceut, West Haven, CT 06516 USA
[2] PDD Dev, Morrisville, NC USA
关键词
D O I
10.1177/0091270002250604
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of food on the pharmacokinetics of vardenafil were examined in 25 healthy adult males. Single-dose vardenafil 20 mg was administered in a randomized four-way crossover design after an overnight fast (at 8 a.m.), after consumption of a high-fat breakfast (at 8 a.m.), on an empty stomach (at 6 p.m.), and after a typical moderate-fat evening meal (at 6 p.m.). Serial blood samples were analyzed for vardenafil and metabolite (M1) levels. When administered after an overnight fast and after a high-fat breakfast, vardenafil geometric mean C-max was 17.14 and 14.0 mug/L, respectively, and AUC was 66.78 and 67.09 mug.h/L, respectively; the median t(max). was 1 hour under fasting conditions and 2 hours with consumption of high-fat breakfast. When administered in the evening on an empty stomach and after a moderate-fat meal, vardenafil geometric mean C-max was 14.22 and 13.04 mug/L, respectively, and AUC was 51.97 and 59.12 mug.h/L, respectively. The median t(max) was 1 hour after fasting or a moderate-fat meal in the evening. All treatments were well tolerated. Thus, while a high-fat meal may alter C-max slightly and delay the absorption up to 1 hour, a moderate-fat meal has no clinically relevant effect on vardenafil pharmacokinetics. Dosage changes ore not warranted based on the wide therapeutic index and the efficacy observed with vardenafil in Phase III studies that were not restricted with respect to food. (C) 2003 the American College of Clinical Pharmacology.
引用
收藏
页码:260 / 267
页数:8
相关论文
共 14 条
[1]  
BISCHOFF E, 2001, PH31060 BAYER PHARM
[2]   Sildenafil citrate: A therapeutic update [J].
Boyce, EG ;
Umland, EM .
CLINICAL THERAPEUTICS, 2001, 23 (01) :2-23
[3]  
Brock Gerald, 2002, European Urology Supplements, V1, P152, DOI 10.1016/S1569-9056(02)80591-7
[4]   Drug, meal and formulation interactions influencing drug absorption after oral administration - Clinical implications [J].
Fleisher, D ;
Li, C ;
Zhou, Y ;
Pao, LH ;
Karim, A .
CLINICAL PHARMACOKINETICS, 1999, 36 (03) :233-254
[5]  
Gbekor E, 2002, J UROLOGY, V167, P246
[6]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[7]  
GOLDSTEIN I, 2001, INT J IMPOT RES, V13, pS64
[8]  
Hellstrom WJG, 2002, J ANDROL, V23, P763
[9]   Drug therapy: Erectile dysfunction. [J].
Lue, TF .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (24) :1802-1813
[10]   Vardenafil [J].
Ormrod, D ;
Easthope, SE ;
Figgitt, DP .
DRUGS & AGING, 2002, 19 (03) :217-227